U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24O2
Molecular Weight 296.4041
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHINYL ESTRADIOL

SMILES

C#C[C@@]1(CC[C@@]2([H])[C@]3([H])CCc4cc(ccc4[C@@]3([H])CC[C@@]21C)O)O

InChI

InChIKey=BFPYWIDHMRZLRN-SLHNCBLASA-N
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H24O2
Molecular Weight 296.4041
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/dosage/ethinyl-estradiol-levonorgestrel.html

Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent. Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH). Used for treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

Originator

Curator's Comment:: Introduced as Estinyl by Schering, US, in 1944

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
LESSINA-21

Approved Use

Indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Launch Date

1.016496E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
122.8 pg/mL
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1335.8 pg × h/mL
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.5 h
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.209
healthy, 14-54
n = 172
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 14-54
Sex: F
Population Size: 172
Sources: Page: p.209
Other AEs: Nausea...
Other AEs:
Nausea (48%)
Sources: Page: p.209
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.209
healthy, 14-54
n = 222
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 14-54
Sex: F
Population Size: 222
Sources: Page: p.209
Other AEs: Vomiting...
Other AEs:
Vomiting (23%)
Sources: Page: p.209
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.211
healthy, 14-54
n = 222
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 14-54
Sex: F
Population Size: 222
Sources: Page: p.211
Other AEs: Mastalgia...
Other AEs:
Mastalgia (32%)
Sources: Page: p.211
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Disc. AE: Dysfunctional uterine bleeding, Uterine bleeding...
AEs leading to
discontinuation/dose reduction:
Dysfunctional uterine bleeding
Uterine bleeding
Headache
Mood change
Nausea
Acne
Weight gain
Sources: Page: p.4
0.595 mg single, oral
Overdose
Dose: 0.595 mg
Route: oral
Route: single
Dose: 0.595 mg
Co-administed with::
cyproterone acetate, p.o(34 mg, single)
Sources:
healthy, 29
n = 1
Health Status: healthy
Age Group: 29
Sex: F
Population Size: 1
Sources:
Disc. AE: Pulmonary embolism...
AEs leading to
discontinuation/dose reduction:
Pulmonary embolism
Sources:
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Pregnancy prevention
Sources: Page: p.1
Disc. AE: Thromboembolic event, Hepatic disease...
AEs leading to
discontinuation/dose reduction:
Thromboembolic event
Hepatic disease
Headache
Hypertension
Uterine bleeding
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Nausea 48%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.209
healthy, 14-54
n = 172
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 14-54
Sex: F
Population Size: 172
Sources: Page: p.209
Vomiting 23%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.209
healthy, 14-54
n = 222
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 14-54
Sex: F
Population Size: 222
Sources: Page: p.209
Mastalgia 32%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.211
healthy, 14-54
n = 222
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 14-54
Sex: F
Population Size: 222
Sources: Page: p.211
Acne Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Dysfunctional uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Headache Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Mood change Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Nausea Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Weight gain Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.4
healthy, 18-41
n = 2185
Health Status: healthy
Condition: Pregnancy prevention
Age Group: 18-41
Sex: F
Population Size: 2185
Sources: Page: p.4
Pulmonary embolism Disc. AE
0.595 mg single, oral
Overdose
Dose: 0.595 mg
Route: oral
Route: single
Dose: 0.595 mg
Co-administed with::
cyproterone acetate, p.o(34 mg, single)
Sources:
healthy, 29
n = 1
Health Status: healthy
Age Group: 29
Sex: F
Population Size: 1
Sources:
Headache Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Pregnancy prevention
Sources: Page: p.1
Hepatic disease Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Pregnancy prevention
Sources: Page: p.1
Hypertension Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Pregnancy prevention
Sources: Page: p.1
Thromboembolic event Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Pregnancy prevention
Sources: Page: p.1
Uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Co-administed with::
levonorgestrel, p.o(0.1 mg; q.d)
Sources: Page: p.1
healthy
Health Status: healthy
Condition: Pregnancy prevention
Sources: Page: p.1
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 1.5 uM]
yes [IC50 14 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4.0
yes [IC50 15 uM]
yes [IC50 19 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4.0
yes [IC50 2.1 uM]
yes [IC50 2.8 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4.0
yes [IC50 24 uM]
yes [IC50 3.3 uM]
yes [IC50 8.3 uM]
yes [IC50 9.2 uM]
yes [IC50 9.2 uM]
yes
weak (co-administration study)
Comment: ~22% increase in clerance of nicotine
Page: 12.0
yes
yes (co-administration study)
Comment: Coadministration with propranolol: ~70% increase in glucuronidation; Coadministration with lamotrigine: ~64% increase in glucuronidation
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The efficacy and tolerability of Valette: a postmarketing surveillance study.
1999 Sep
Differential expression of canalicular membrane Ca2+/Mg(2+)-ecto-ATPase in estrogen-induced and obstructive cholestasis in the rat.
2000 Aug
A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
2000 Dec
A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system.
2000 Feb
Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH).
2000 Nov
Differential estrogen receptor binding of estrogenic substances: a species comparison.
2000 Nov 15
Biphasic versus monophasic oral contraceptives for contraception.
2001
Synthetic estrogens-mediated activation of JNK intracellular signaling molecule.
2001 Apr
High metabolization of catecholestrogens by type 1 estrogen sulfotransferase (hEST1).
2001 Apr
Oestrogens and oestrogenic activity in raw and treated water in Severn Trent Water.
2001 Apr
Fine structure of prolactin cell of female albino rat as affected by some antifertility drugs--a comparative electron microscopic study.
2001 Feb
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
2001 Feb
Differential in vitro suppressive effects of steroids on leukocyte phagocytosis in two teleosts, tilapia and common carp.
2001 Feb
Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-beta activity in SAOS-2 and LNCaPLN3 cells.
2001 Feb
Effects of age and weaning on the immature rat uterotrophic assay using ethynylestradiol.
2001 Jan
Influence of low-dose oral contraceptives, alcohol, and grapefruit on.
2001 Jan
Lack of effect of alcohol on ethinylestradiol in premenopausal women.
2001 Jan
Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol.
2001 Jan
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
2001 Jan
Charcoal treatment and risk of escape ovulation in oral contraceptive users.
2001 Jan
Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.
2001 Jan
Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol.
2001 Jan
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
2001 Jul
Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over.
2001 Jun
Clinical recommendations for oxcarbazepine.
2001 Mar
Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature.
2001 Mar
Applicability of micellar electrokinetic chromatography to the analysis of estrogens in water.
2001 Mar
Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
2001 Mar
Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse.
2001 Mar
Induction of gene expression in sheepshead minnows (Cyprinodon variegatus) treated with 17beta-estradiol, diethylstilbestrol, or ethinylestradiol: the use of mRNA fingerprints as an indicator of gene regulation.
2001 Mar
Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism.
2001 Mar
Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction-liquid chromatography-diode array detection.
2001 Mar 16
Testosterone 5alpha-reductase inhibitory active constituents from Anemarrhenae Rhizoma.
2001 May
Streamlined beta-galactosidase assay for analysis of recombinant yeast response to estrogens.
2001 May
Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol.
2001 May
Patents

Sample Use Guides

Usual Adult Dose for Endometriosis Ethinyl estradiol-levonorgestrel products are packaged in 21 or 28 day dosage preparations. The last seven tablets in 28 day dosage preparations are hormonally inert. Regardless of the number of tablets in a package, the cycle length for oral contraceptives is generally considered to be 28 days.
Route of Administration: Oral
EE (
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:52:39 UTC 2021
Edited
by admin
on Fri Jun 25 20:52:39 UTC 2021
Record UNII
423D2T571U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHINYL ESTRADIOL
EMA EPAR   HSDB   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
ORSYTHIA COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ORTHO-CEPT
Common Name English
OVRAL COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF PREVIFEM
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SEASONIQUE
Common Name English
ETHINYL ESTRADIOL [VANDF]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ALESSE
Common Name English
FEMCON FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ESTROSTEP FE
Common Name English
MINASTRIN 24 FE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF TRI LO SPRINTEC
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SEASONALE
Common Name English
MARLISSA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ISIBLOOM COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF DESOGEN
Common Name English
KELNOR COMPONENT ETHINYL ESTRADIOL
Common Name English
ZOVIA COMPONENT ETHINYL ESTRADIOL
Brand Name English
AVIANE COMPONENT ETHINYL ESTRADIOL
Brand Name English
QUARTETTE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL [HSDB]
Common Name English
ETHINYL ESTRADIOL [USP-RS]
Common Name English
NSC-10973
Code English
ETHINYL ESTRADIOL COMPONENT OF INTROVALE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF KELNOR
Common Name English
ELIFEMME COMPONENT ETHINYL ESTRADIOL
Brand Name English
LYNORAL
Brand Name English
KURVELO COMPONENT ETHINYL ESTRADIOL
Common Name English
SEASONIQUE COMPONENT ETHINYL ESTRADIOL
Common Name English
ORTHO TRI-CYCLEN COMPONENT ETHINYL ESTRADIOL
Common Name English
NORQUEST FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF VELIVET
Common Name English
PREVIFEM COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF MIRCETTE
Common Name English
YAZ COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ORTHO TRI-CYCLEN
Common Name English
ETHINYL ESTRADIOL [MI]
Common Name English
LYBREL COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TWIRLA
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF LEVONEST
Common Name English
BEYAZ COMPONENT ETHINYL ESTRADIOL
Common Name English
TRI-SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [EMA EPAR]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF YAZ
Common Name English
ETHINYL ESTRADIOL COMPONENT OF ALTAVERA
Common Name English
SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOLUM [WHO-IP LATIN]
Common Name English
CYCLESSA COMPONENT ETHINYL ESTRADIOL
Common Name English
ESTROSTEP FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOL
EP   INCI   INN   MART.   WHO-DD   WHO-IP  
INCI   INN  
Official Name English
ETHINYLESTRADIOL [INCI]
Common Name English
PORTIA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYLESTRADIOL [EP MONOGRAPH]
Common Name English
LEVORA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF BEYAZ
Common Name English
ENSKYCE COMPONENT ETHINYL ESTRADIOL
Brand Name English
TWIRLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
17-ETHINYLESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TRI-SPRINTEC
Common Name English
ARANELLE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SAFYRAL
Common Name English
ETHINYLESTRADIOL [MART.]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF YASMIN
Common Name English
NORDETTE COMPONENT ETHINYL ESTRADIOL
Brand Name English
XULANE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ESTINYL
Brand Name English
ETHINYLESTRADIOL [WHO-DD]
Common Name English
QUASENSE COMPONENT ETHINYL ESTRADIOL
Common Name English
TAYTULLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYLESTRADIOL [INN]
Common Name English
ETHINYLOESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TRI-PREVIFEM
Common Name English
ETHINYL ESTRADIOL COMPONENT OF OVRAL
Common Name English
PIMTREA COMPONENT ETHINYL ESTRADIOL
Brand Name English
SAFYRAL COMPONENT ETHINYL ESTRADIOL
Common Name English
INTROVALE COMPONENT ETHINYL ESTRADIOL
Common Name English
TRIVORA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF LOSEASONIQUE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF QUASENSE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF CRYSELLE
Common Name English
KARIVA COMPONENT ETHINYL ESTRADIOL
Common Name English
ORTHO-CEPT COMPONENT ETHINYL ESTRADIOL
Common Name English
LO MINASTRIN FE COMPONENT ETHINYL ESTRADIOL
Brand Name English
FEMINONE
Brand Name English
TRI-PREVIFEM COMPONENT ETHINYL ESTRADIOL
Common Name English
YASMIN COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF LEVLITE
Common Name English
NUVARING COMPONENT ETHINYL ESTRADIOL
Common Name English
TRI LO SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ANNOVERA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF KARIVA
Common Name English
ALTAVERA COMPONENT ETHINYL ESTRADIOL
Common Name English
MIRCETTE COMPONENT ETHINYL ESTRADIOL
Common Name English
VYFEMLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF ARANELLE
Common Name English
LO LOESTRIN FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [ORANGE BOOK]
Common Name English
ETHINYL ESTRADIOL COMPONENT OF PREVEN
Common Name English
ENPRESSE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ALESSE COMPONENT ETHINYL ESTRADIOL
Common Name English
CRYSELLE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOL [WHO-IP]
Common Name English
LEVLITE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF LO LOESTRIN FE
Common Name English
SETLAKIN COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF NUVARING
Common Name English
VOLNEA COMPONENT ETHINYL ESTRADIOL
Brand Name English
DESOGEN COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF SETLAKIN
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF SPRINTEC
Common Name English
VELIVET COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF TRI-LEGEST FE
Common Name English
ETHINYL ESTRADIOL COMPONENT OF CYCLESSA
Common Name English
17ALPHA-ETHINYLESTRADIOL
Common Name English
PREVEN COMPONENT ETHINYL ESTRADIOL
Common Name English
LOSEASONIQUE COMPONENT ETHINYL ESTRADIOL
Common Name English
VIENVA COMPONENT ETHINYL ESTRADIOL
Brand Name English
19-NOR-17.ALPHA.-PREGNA-1,3,5(10)-TRIEN-20-YNE-3,17-DIOL
Common Name English
TRI-LEGEST FE COMPONENT ETHINYL ESTRADIOL
Common Name English
FEMHRT COMPONENT ETHINYL ESTRADIOL
Common Name English
LESSINA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF ANNOVERA
Brand Name English
BEKYREE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF FEMHRT
Common Name English
ETHINYL ESTRADIOL COMPONENT OF LYBREL
Common Name English
ETHINYL ESTRADIOL COMPONENT OF FEMCON FE
Common Name English
SEASONALE COMPONENT ETHINYL ESTRADIOL
Common Name English
TRIPHASIL COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL COMPONENT OF NORQUEST FE
Common Name English
VIORELE COMPONENT ETHINYL ESTRADIOL
Brand Name English
NORINYL COMPONENT ETHINYL ESTRADIOL
Brand Name English
19-NORPREGNA-1,3,5(10)-TRIEN-20-YNE-3,17-DIOL, (17.ALPHA.)-
Common Name English
BREVICON COMPONENT ETHINYL ESTRADIOL
Brand Name English
LEVONEST COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QG03AA06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
NDF-RT N0000000100
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/LEV)
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA13
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA10
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03CA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QL02AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
NDF-RT N0000175825
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA15
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/NOR)
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
NCI_THESAURUS C478
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA12
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA16
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA12
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA08
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03CA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA09
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA10
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
FDA ORPHAN DRUG 28788
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA08
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB05
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB07
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
LIVERTOX 382
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB04
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA11
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA13
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA16
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA15
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA09
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AA01
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AB06
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
EMA ASSESSMENT REPORTS EVRA (AUTHORIZED: CONTRACEPTION)
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-VATC QG03AA11
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC G03AB02
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
WHO-ATC L02AA03
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
Code System Code Type Description
EVMPD
SUB07277MIG
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
FDA UNII
423D2T571U
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
PUBCHEM
5991
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
NCI_THESAURUS
C486
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ETHINYL ESTRADIOL
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY Description: A white to slightly yellowish white, crystalline powder; odourless.Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS; soluble in acetone R and dioxan R.Category: Estrogen.Storage: Ethinylestradiol should be kept in a well-closed container, protected from light.Additional information: Ethinylestradiol may exist in 2 polymorphic forms one of which melts at about 183?C, the other, metastable, at about 143?C.RequirementsDefinition: Ethinylestradiol contains not less than 97.0% and not more than 102.0% of C20H24O2, calculated with reference to the dried substance.
ChEMBL
CHEMBL691
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
DRUG BANK
DB00977
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
MERCK INDEX
M5058
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY Merck Index
MESH
D004997
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
LACTMED
Ethinyl Estradiol
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
EPA CompTox
57-63-6
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-342-2
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
RXCUI
4124
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1260001
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY USP-RS
INN
437
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
IUPHAR
7071
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
DRUG CENTRAL
1082
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
CAS
57-63-6
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
HSDB
3587
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
WIKIPEDIA
ETHINYL ESTRADIOL
Created by admin on Fri Jun 25 20:52:39 UTC 2021 , Edited by admin on Fri Jun 25 20:52:39 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
DERIVATIVE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
PLASMA
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY